Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)

Completed · Phase 1/Phase 2

Conditions studied: Glomerulonephritis, Membranous, antiPLA2R Positive

In brief

This is an open-label, multicentre study to characterize the safety and efficacy of the human anti-CD38 antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory)

Key facts

Study ID
NCT04145440
Run by
HI-Bio, A Biogen Company
People needed
31
Starts
2019-10-15
Expected to finish
2022-08-02
Last updated by the study team
2025-02-24

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.